Meningococcal Disease


PUBLISHED: 2021 CATEGORY: Health care providers TYPE: External Link Canadian Immunization Guide: Evergreen Edition

Canadian Immunization Guide: Evergreen Edition

Evergreen edition presents information on the immunizing agents available in Canada and their use in the prevention of communicable diseases.

Corporate Authors: National Advisory Committee on Immunization
Publisher: Public Health Agency of Canada

PUBLISHED: 2021 CATEGORY: Les fournisseurs de soins TYPE: External Link Guide canadien d'immunisation : Edition évolutive

Guide canadien d'immunisation : Edition évolutive

Le présent Guide (édition évolutive) contient des renseignements sur les agents immunisants disponibles au Canada et sur leur utilisation en vue de prévenir les maladies transmissibles.

Corporate Authors: Comité consultatif national de l'immunisation
Publisher: Agence de la santé publique du Canada

PUBLISHED: 2020 CATEGORY: Health care providers TYPE: External Link The Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease

The Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease

Corporate Authors: National Advisory Committee on Immunization
Publisher: Public Health Agency of Canada

PUBLISHED: 2020 CATEGORY: Les fournisseurs de soins TYPE: External Link Utilisation du vaccin bivalent dirigé contre la protéine de liaison au facteur H (MenB-fHBP) pour la prévention de l’infection à méningocoque du sérogroupe B

Utilisation du vaccin bivalent dirigé contre la protéine de liaison au facteur H (MenB-fHBP) pour la prévention de l’infection à méningocoque du sérogroupe B

Corporate Authors: Comité consultatif national de l'immunisation
Publisher: Agence de la santé publique du Canada

PUBLISHED: 2018 CATEGORY: Les fournisseurs de soins TYPE: External Link Mise à jour sur la vaccination contre la méningococcie invasive chez les enfants et les adolescents canadiens

Mise à jour sur la vaccination contre la méningococcie invasive chez les enfants et les adolescents canadiens

Invasive meningococcal disease (IMD) is serious, often resulting in fulminant sepsis or meningitis. IMD in Canada is primarily attributable to serogroups B and C. There are routine programs for serogroup C vaccine at 12 months of age, with some jurisdictions routinely providing additional earlier doses. Adolescents routinely receive a booster dose of serogroup C vaccine or of a quadrivalent (serogroups A, C, W and Y) vaccine. Serogroup B vaccines are not recommended for routine use pending further data on the efficacy and duration of protection from the available vaccine. However, children at increased risk for IMD should start immunization for serogroups B and C as soon as possible, assuming that they are at least 2 months of age.

Authors: Robinson JL
Journal Issue: 1
Journal Title: Paediatrics & Child Health
Journal Volume: 23
Publisher: Oxford Academic

PUBLISHED: 2018 CATEGORY: Health care providers TYPE: External Link Update on invasive meningococcal vaccination for Canadian children and youth

Update on invasive meningococcal vaccination for Canadian children and youth

Invasive meningococcal disease (IMD) is serious, often resulting in fulminant sepsis or meningitis. IMD in Canada is primarily attributable to serogroups B and C. There are routine programs for serogroup C vaccine at 12 months of age, with some jurisdictions routinely providing additional earlier doses. Adolescents routinely receive a booster dose of serogroup C vaccine or of a quadrivalent (serogroups A, C, W and Y) vaccine. Serogroup B vaccines are not recommended for routine use pending further data on the efficacy and duration of protection from the available vaccine. However, children at increased risk for IMD should start immunization for serogroups B and C as soon as possible, assuming that they are at least 2 months of age.

Authors: Robinson JL
Journal Issue: 1
Journal Title: Paediatrics & Child Health
Journal Volume: 23
Publisher: Oxford Academic

PUBLISHED: 2017 CATEGORY: Les fournisseurs de soins TYPE: External Link Augmentation des infections invasives à Neisseria meningitidis de sérogroupe W au Canada de 2009 à 2016

Augmentation des infections invasives à Neisseria meningitidis de sérogroupe W au Canada de 2009 à 2016

La prévalence de la méningococcie à MenW augmente au Canada et est associée à une augmentation des cas attribuables au complexe clonal ST-11 émergent, qui a maintenant été identifié dans cinq provinces canadiennes. Il semble plus courant chez les patients âgés que le complexe clonal ST-22 traditionnel, plus répandu chez les jeunes patients.

Authors: Tsang RSW et al.
Journal Issue: 7-8
Journal Title: Relevé des maladies transmissibles au Canada
Journal Volume: 43
Publisher: Agence de la santé publique du Canada

PUBLISHED: 2017 CATEGORY: Health care providers TYPE: External Link Immunization for meningococcal serogroup B: What does the practitioner need to know?

Immunization for meningococcal serogroup B: What does the practitioner need to know?

Most invasive meningococcal disease in Canada is now caused by serogroup B organisms. A vaccine directed against this serogroup (4CMenB) is newly licensed in Canada. It is hoped that this document will be useful to clinicians when faced with questions from parents.

Authors: Robinson J
Corporate Authors: Canadian Paediatric Society - Infectious Diseases and Immunization Committee
Publisher: Canadian Paediatric Society

PUBLISHED: 2017 CATEGORY: Health care providers TYPE: External Link Increase in Neisseria meningitidis serogroup W invasive disease in Canada: 2009–2016

Increase in Neisseria meningitidis serogroup W invasive disease in Canada: 2009–2016

MenW meningococcal disease is growing in prevalence in Canada and is associated with an increase in the emerging ST-11 CC. This emerging clonal complex has now been identified in five provinces in Canada. It appears to be more common in older patients than the traditional ST-22 CC, which occurs more often in younger patients.

Authors: Tsang RSW et al.
Journal Issue: 7-8
Journal Title: Canada Communicable Disease Report
Journal Volume: 43
Publisher: Public Health Agency of Canada

PUBLISHED: 2017 CATEGORY: Les fournisseurs de soins TYPE: External Link La vaccination contre le méningocoque du sérogroupe B : ce que le praticien doit savoir

La vaccination contre le méningocoque du sérogroupe B : ce que le praticien doit savoir

Au Canada, la plupart des méningococcies invasives sont désormais causées par des organismes du sérogroupe B. Un vaccin conçu contre ce sérogroupe (4CMenB) vient d'être homologué au Canada. Le présent document peut être utile aux cliniciens qui devront répondre aux questions des parents.

Authors: Robinson J
Corporate Authors: Société canadienne de pédiatrie, Comité des maladies infectieuses et d’immunisation
Publisher: Société canadienne de pédiatrie